A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections
Purwati, Budiono, Brian Eka Rachman, Yulistiani, Andang Miatmoko, Nasronudin, Soroy Lardo, Yongki Iswandi Purnama, Mafidhatul Laely, Ike Rochmad, Taufik Ismail, Sri Wulandari, Dwi Setyawan, Alfian Nur Rosyid, Herley Windo Setiawan, Prastuti Asta Wulaningrum, Tri Pudy Asmarawati, Erika Marfiani, Shinta Karina Yuniati, Muhammad Rabiul Fuadi, Pepy Dwi Endraswari, Purwaningsih, Eryk Hendrianto, Deya Karsari, Aristika Dinaryanti, Nora Ertanti, Igo Syaiful Ihsan, Disca Sandyakala Purnama, Yuni Indrayani
Biochemistry Research International, doi:10.1155/2021/6685921
ritonavir and 500 mg of azithromycin; and Group E treated with a 400/100 mg dose of lopinavir/ritonavir and 200 mg of doxycycline. Results. 754 subjects participated in this study: 694 patients (92.4%) who presented mild symptoms and 57 patients (7.6%) classified as suffering from a moderate case of COVID-19. On the third day after treatment, 91.7%-99.2% of the subjects in Groups A-E were confirmed negative by a PCR swab test compared to 26.9% in the Control group. Observation of all groups which experienced a significant decrease in virus load between day 1 and day 7 was undertaken. Other markers, such as CRP and IL-6, were significantly lower in all treatment groups (p < 0.05 and p < 0.0001) than in the Control group. Furthermore, IL-10 and TNF-α levels were significantly elevated in all treatment groups (p < 0.0001). e administration of azithromycin to the Control group increased CRP and IL-6 levels, while reduced IL-10 and TNF-α on day 7 (p < 0.0001) compared with day 1. Decreases in ALT and AST levels were observed in all groups (p < 0.0001). ere was an increase in creatinine in the serum level of the Control, C, D, and E groups (p < 0.05), whereas the BUN level was elevated in all groups (p < 0.0001). Conclusions. e study findings suggest that the administration of lopinavir/ritonavir-doxycycline, lopinavir/ritonavir-azithromycin, and azithromycinhydroxychloroquine as a dual drug combination produced a significantly rapid PCR conversion rate to negative in three-day treatment of mild to moderate COVID-19 cases. Further studies should involve observation of older patients with severe clinical symptoms in order to collate significant amounts of demographic data.
Ethical Approval e researchers conducted the clinical trials across multicenter sites through collaboration between Universitas Airlangga, the Indonesian Intelligence Agency (BIN), and the Indonesian National Army (TNI-AD). is study was conducted in strict accordance with the approved clinical trial protocols (PPUK) provided by BPOM (No. PP.01.01.1.3.07.20.06) with an additional letter of approval from the National Institute of Health Research and Development, Indonesian Ministry of Health (Balitbangkes Kementerian Kesehatan RI), and ethical approval no. 159/KEP/2020 issued by the Ethics Committee of Universitas Airlangga Hospital (RS UNAIR) on June 23, 2020. e documents submitted to secure PPUK clearance can be found at the following URL: https://www.ina-registry.org/?act� registry_trial_detail&code_trial�11202034090121TX6YYSS.
Conflicts of Interest e authors declare no conflicts of interest regarding this work.
References
Abbasifard, Khorramdelazad, e bio-mission of interleukin-6 in the pathogenesis of COVID-19: a brief look at potential therapeutic tactics, Life Sciences
Batteux, Bodeau, Gras-Champel, Abnormal laboratory findings and plasma concentration monitoring of lopinavir and ritonavir in COVID-19, British Journal of Clinical Pharmacology
Bertolini, Van De Peppel, Bodewes, Abnormal liver function tests in COVID-19 patients: relevance and potential pathogenesis, Hepatology
Bruce, Liang, Report of the WHO-China Joint Mission on Coronavirus Disease
Cao, Wang, Wen, A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19, e New England Journal of Medicine
Cascella, Rajnik, Cuomo, Dulebohn, Napoli, Features, Evaluation and Treatment of Coronavirus
Chen, Zhang, Wei, Association between cytokine profiles and lung injury in COVID-19 pneumonia, Respiratory Research
Chien, Hsueh, Hsueh, Yu, Yang, Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome, Respirology
Choy, Wong, Kaewpreedee, Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro, Antiviral Research
Coomes, Haghbayan, Interleukin-6 in Covid-19: a systematic review and meta-analysis, Reviews in Medical Virology
Eljaaly, Al-Tawfiq, Crushing lopinavir-ritonavir tablets may decrease the efficacy of therapy in COVID-19 patients, Travel Medicine and Infectious Disease
Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, International Journal of Antimicrobial Agents
Herold, Jurinovic, Arnreich, Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19, Journal of Allergy and Clinical Immunology
Huang, Tang, Xu, No statistically apparent difference in antiviral effectiveness observed among ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate coronavirus disease 2019: results of a randomized, open-labeled prospective study, Frontiers in Pharmacology
Hundt, Deng, Ciarleglio, Nathanson, Lim, Abnormal liver tests in COVID-19: a retrospective observational cohort study of 1827 patients in a major US hospital network, Hepatology
Hung, Lung, Tso, Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial, e Lancet
Hunter, Jones, IL-6 as a keystone cytokine in health and disease, Nature Immunology
Hussman, Cellular and molecular pathways of COVID-19 and potential points of therapeutic intervention, Frontiers in Pharmacology
Kim, Kim, Kwon, Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019, e Korean Journal of Internal Medicine
Li, Akbarshahi, Bjermer, Uller, Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients, Scientific Reports
Li, Zu, Li, Azithromycin protects against Zika virus infection by upregulating virus-induced type I and III interferon responses, Antimicrobial Agents and Chemotherapy
Luo, Liu, Jiang, Yue, Liu et al., IL-6 and CD8+ T cell counts combined are an early predictor of inhospital mortality of patients with COVID-19, JCI Insight
Min, Cheon, Ha, Sohn, Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity, Scientific Reports
Tanriverd, Ört Ük, Yildirim, e use of hydroxychloroquine plus azithromycin and early hospital admission are beneficial in Covid-19 patients: Turkey experience with real-life data, Turkish journal of medical sciences
Wang, Fei, Zhao, Yu, IL-6 may be a good biomarker for earlier detection of COVID-19 progression, Intensive Care Medicine
Wang, Tseng, Yen, Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins, Biochemical and Biophysical Research Communications
Wang, Wu, Zhang, C-reactive protein level may predict the risk of COVID-19 aggravation, Open Forum Infectious Diseases
Wu, Zhao, Qu, Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients, medRxiv
Xu, Yu, Shen, Analysis of inflammatory parameters and disease severity for 88 hospitalized COVID-19 patients in Wuhan, China, International Journal of Medical Sciences
Yao, Ye, Zhang, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clinical Infectious Diseases
Zengyu, Huang, Guo, Association of inflammatory markers with the severity of COVID-19: a metaanalysis, International Journal of Infectious Diseases
Zhang, Wang, Yue, Nucleocapsid protein of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-κB, Virology
Zhang, Zhou, Yan, Correlation between cytokines and coagulation-related parameters in patients with coronavirus disease 2019 admitted to ICU, Clinica Chimica Acta
